Jeff Yass’s X4 Pharmaceuticals XFOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.17M Buy
+250,300
New +$1.03M ﹤0.01% 7804
2026
Q1
Sell
-127,900
Closed -$512K 14240
2025
Q4
$512K Hold
127,900
﹤0.01% 8730
2025
Q3
$437K Hold
127,900
﹤0.01% 9265
2025
Q2
$243K Buy
127,900
+122,477
+2,258% +$501K ﹤0.01% 10810
2025
Q1
$39K Sell
5,423
-2,360
-30% -$32.5K ﹤0.01% 11935
2024
Q4
$170K Buy
7,783
+3,223
+71% +$51.4K ﹤0.01% 10903
2024
Q3
$91.7K Sell
4,560
-763
-14% -$15.9K ﹤0.01% 11100
2024
Q2
$92.6K Buy
5,323
+1,240
+30% +$40.6K ﹤0.01% 11071
2024
Q1
$170K Buy
4,083
+3,130
+328% +$87.1K ﹤0.01% 10776
2023
Q4
$24K Buy
953
+293
+44% +$7.13K ﹤0.01% 11934
2023
Q3
$21.6K Sell
660
-2,110
-76% -$92K ﹤0.01% 11580
2023
Q2
$161K Buy
2,770
+2,387
+623% +$123K ﹤0.01% 10503
2023
Q1
$10K Sell
383
-2,850
-88% -$83.6K ﹤0.01% 12208
2022
Q4
$96K Buy
+3,233
New +$153K ﹤0.01% 10995
2022
Q1
Sell
-1,603
Closed -$110K 14106
2021
Q4
$110K Sell
1,603
-147
-8% -$18.6K ﹤0.01% 12078
2021
Q3
$278K Buy
+1,750
New +$288K ﹤0.01% 10768

Other funds holding XFOR

Jeff Yass's XFOR Position: Q2 2026 in Review

Jeff Yass reduced its X4 Pharmaceuticals (XFOR) stake by 98% in Q2 2026, selling an estimated $3.46M and leaving 14,050 shares worth $65.6K. The position accounts for ﹤0.01% of the portfolio, ranked #12725.

Jeff Yass first reported a position in XFOR in Q2 2019 and has held it in 20 quarters since. The position peaked at $3.54M in Q1 2026. 88 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • Jeff Yass held 14,050 shares of X4 Pharmaceuticals worth $65.6K as of Q2 2026.
  • Jeff Yass sold 842,172 X4 Pharmaceuticals shares in Q2 2026, an estimated $3.46M.
  • X4 Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12725 holding.
  • Jeff Yass first reported a position in X4 Pharmaceuticals in Q2 2019 and has held it in 20 quarters since.
  • Jeff Yass's X4 Pharmaceuticals position peaked at $3.54M in Q1 2026.
  • 88 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.